Impedimed Limited Statistics
Want to see AU:IPD full AI Analyst Report?
Impedimed Limited (IPD) Stock Statistics & Valuation Metrics
Total Valuation
Impedimed Limited has a market cap or net worth of AUD 11.00M. The enterprise value is AUD 12.52M.
- Market Cap
- AUD 11.00M
- Enterprise Value
- AUD 12.52M
Share Statistics
Impedimed Limited has 3,665,999,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 3,665,999,000
- Owned by Insiders
- 3.36%
- Owned by Institutions
- <0.01%
Financial Efficiency
Impedimed Limited’s return on equity (ROE) is -2.44 and return on invested capital (ROIC) is -73.32%.
- Return on Equity (ROE)
- -2.44
- Return on Assets (ROA)
- -0.72
- Return on Invested Capital (ROIC)
- -73.32%
- Return on Capital Employed (ROCE)
- -0.78
- Revenue Per Employee
- 221.41K
- Profits Per Employee
- -377.38K
- Employee Count
- 66
- Asset Turnover
- 0.42
- Inventory Turnover
- 11.99
Valuation Ratios
The current PE Ratio of Impedimed Limited is -0.34. Impedimed Limited’s PEG ratio is 0.30.
- PE Ratio
- -0.34
- PS Ratio
- 1.00
- PB Ratio
- 0.88
- Price to FCF
- 0.00
- Price to Operating Cash Flow
- -0.45
- PEG Ratio
- 0.30
Income Statement
In the last 12 months, Impedimed Limited had revenue of 14.61M and earned -24.91M in profits. Earnings per share was -0.01.
- Revenue
- 14.61M
- Gross Profit
- -11.89M
- Operating Income
- -22.11M
- Pretax Income
- -26.09M
- Net Income
- -24.91M
- EBITDA
- -22.11M
- Earnings Per Share (EPS)
- -0.01
Cash Flow
In the last 12 months, operating cash flow was -20.03M and capital expenditures 20.03M, giving a free cash flow of 0 billion.
- Operating Cash Flow
- -20.03M
- Free Cash Flow
- 0
- Free Cash Flow per Share
- 0.00
Dividends & Yields
Impedimed Limited pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.00%
- Earnings Yield
- -277.79%
Stock Price Statistics
- Beta
- 2.43
- 52-Week Price Change
- -64.10%
- 50-Day Moving Average
- 0.01
- 200-Day Moving Average
- 0.03
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Impedimed Limited upcoming earnings date is Nov 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Nov 04, 2027
- Ex-Dividend Date
- ―
Financial Position
Impedimed Limited as a current ratio of 3.81, with Debt / Equity ratio of 162.91%
- Current Ratio
- 3.81
- Quick Ratio
- 3.45
- Debt to Market Cap
- 1.51
- Net Debt to EBITDA
- -0.06
- Interest Coverage Ratio
- -5.93
Taxes
In the past 12 months, Impedimed Limited has paid -1.18M in taxes.
- Income Tax
- -1.18M
- Effective Tax Rate
- 0.05
Enterprise Valuation
Impedimed Limited EV to EBITDA ratio is -1.06, with an EV/FCF ratio of 0.00.
- EV to Sales
- 1.09
- EV to EBITDA
- -1.06
- EV to Free Cash Flow
- 0.00
- EV to Operating Cash Flow
- -0.80
Balance Sheet
Impedimed Limited has AUD 15.29M in cash and marketable securities with AUD 16.60M in debt, giving a net cash position of -AUD 1.31M billion.
- Cash & Marketable Securities
- AUD 15.29M
- Total Debt
- AUD 16.60M
- Net Cash
- -AUD 1.31M
- Net Cash Per Share
- AUD 0.00
- Tangible Book Value Per Share
- AUD 0.00
Margins
Gross margin is -81.36%, with operating margin of -117.21%, and net profit margin of -170.44%.
- Gross Margin
- -81.36%
- Operating Margin
- -117.21%
- Pretax Margin
- -172.08%
- Net Profit Margin
- -170.44%
- EBITDA Margin
- -102.78%
- EBIT Margin
- -117.21%
Analyst Forecast
The average price target for Impedimed Limited is AUD 0.01, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- AUD 0.01
- Price Target Upside
- 28.57% Downside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- 14.85%
- EPS Growth Forecast
- -1.74%
Scores
- Smart Score
- 5
- AI Score
- 48
